Granahan Investment Management LLC Has $6.01 Million Stake in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Granahan Investment Management LLC cut its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 2.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,430,151 shares of the medical instruments supplier’s stock after selling 32,306 shares during the quarter. Granahan Investment Management LLC owned 3.39% of Harvard Bioscience worth $6,007,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in HBIO. B. Riley Asset Management LLC raised its position in Harvard Bioscience by 85.8% during the fourth quarter. B. Riley Asset Management LLC now owns 3,187,296 shares of the medical instruments supplier’s stock valued at $8,829,000 after purchasing an additional 1,472,061 shares in the last quarter. Boothbay Fund Management LLC boosted its stake in shares of Harvard Bioscience by 173.2% in the 4th quarter. Boothbay Fund Management LLC now owns 1,072,829 shares of the medical instruments supplier’s stock valued at $2,972,000 after purchasing an additional 680,117 shares in the last quarter. Meros Investment Management LP grew its holdings in shares of Harvard Bioscience by 54.4% during the 4th quarter. Meros Investment Management LP now owns 1,136,845 shares of the medical instruments supplier’s stock valued at $3,149,000 after purchasing an additional 400,411 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Harvard Bioscience by 410.7% during the 2nd quarter. Millennium Management LLC now owns 390,966 shares of the medical instruments supplier’s stock valued at $1,407,000 after purchasing an additional 314,413 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Harvard Bioscience during the 3rd quarter worth approximately $673,000. Institutional investors own 76.06% of the company’s stock.

Insider Buying and Selling

In related news, CEO James W. Green bought 25,000 shares of the stock in a transaction that occurred on Thursday, August 17th. The stock was acquired at an average cost of $4.38 per share, with a total value of $109,500.00. Following the transaction, the chief executive officer now directly owns 2,862,679 shares in the company, valued at $12,538,534.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.20% of the stock is currently owned by insiders.

Harvard Bioscience Stock Performance

Harvard Bioscience stock opened at $4.18 on Monday. The business has a 50 day moving average of $4.75 and a 200-day moving average of $4.74. The company has a market capitalization of $178.44 million, a P/E ratio of -32.15 and a beta of 1.62. Harvard Bioscience, Inc. has a 1 year low of $1.98 and a 1 year high of $6.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.29 and a quick ratio of 1.16.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Tuesday, August 8th. The medical instruments supplier reported $0.03 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.03. The firm had revenue of $28.76 million for the quarter, compared to analyst estimates of $29.50 million. Harvard Bioscience had a negative net margin of 4.76% and a positive return on equity of 3.01%. On average, equities research analysts predict that Harvard Bioscience, Inc. will post 0.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a research note on Monday, September 4th.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.